Amicogen Inc is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâ€™s products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company sells its products in domestic and overseas markets.

Employees

236

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-23	₩1,233.00	+5.38%	593,257
26-07-22	₩1,170.00	+1.83%	255,738
26-07-21	₩1,149.00	+0.97%	332,833
26-07-20	₩1,138.00	-2.65%	381,883
26-07-16	₩1,169.00	-4.18%	982,141

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 2026-07-23			5-day change	1st Jan Change
1,233.00 ^KRW	+5.38%		+5.47%	-30.81%

06-21	Amicogen, Inc. announced that it expects to receive KRW 9.9999989 billion in funding	CI
05-14	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	86.87B 58.88M 51.79M 48.11M 44.25M 82.98M 5.7B 84.47M 575M 224M 2.78B 221M 216M 9.65B	P/E 2024	-4.02x	P/E 2025	-3.28x
Enterprise Value	174B 118M 104M 96.25M 88.52M 166M 11.41B 169M 1.15B 449M 5.56B 442M 433M 19.3B	EV / Sales 2024	1.86x	EV / Sales 2025	4.43x
Free-Float	95.04%	Yield 2024 *	-	Yield 2025	-

06-21	Amicogen, Inc. announced that it expects to receive KRW 9.9999989 billion in funding	CI
05-14	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-23	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-14	Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-09-21	Amicogen, Inc.(KOSDAQ:A092040) added to S&P Global BMI Index	CI
25-08-20	Bio-Works Launches WorkBeads AffimAb Edge: Strategic Expansion in the Protein A Resin Market	CI
25-08-14	Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-11	Amicogen, Inc. announced that it has received KRW 7 billion in funding from BIFIDO Co., Ltd.	CI
25-05-14	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-24	Amicogen, Inc.(KOSDAQ:A092040) dropped from S&P Global BMI Index	CI
25-03-19	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-12-09	An undisclosed buyer agreed to acquire an unknown stake in Amicogen Biopharm Co., Ltd. from Amicogen, Inc. for KRW 54.7 billion.	CI
24-11-20	Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc..	CI

24-06-20	Bio-Works and Amicogen have concluded their technology transfer project.	AQ
21-09-10	Bio Works Technologies : Amicogen Inc enters into agreement to divest its ownership in Bio-Works	AQ
21-02-17	Bio Works Technologies : Works signs licensing agreement with Amicogen Inc to establish local manufacturing of agarose resins in South Korea	AQ

Amicogen, Inc. Stock

Stocks

A092040

KR7092040005

Biotechnology & Medical Research

Valuation: Amicogen, Inc.

Chart: Amicogen, Inc.

Latest news : Amicogen, Inc.

Press Releases: Amicogen, Inc.

News in other languages: Amicogen, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Amicogen, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+5.38%
1 week	+5.47%
Current month	-16.75%
1 month	-28.73%
3 months	-31.19%
6 months	-27.56%
Current year	-30.81%

1 week	1,117	1,280
1 month	1,104	1,770
Current year	1,104	2,300
1 year	1,104	4,400
3 years	1,104	9,400
5 years	1,104	22,000
10 years	1,104	24,825

Manager	Title	Age	Since
Jjeo Pyo CEO	Chief Executive Officer	53	-
Young-Chul Yoon PRN	Corporate Officer/Principal	55	2024-03-27
Chun-Gu Kim AUD	Comptroller/Controller/Auditor	69	2025-03-26

Director	Title	Age	Since
Jun-Ho Kim BRD	Director/Board Member	56	2025-02-25
Soon-Yong Kim BRD	Director/Board Member	58	2025-02-25
Young-Chul Yoon BRD	Director/Board Member	55	2024-03-27

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/3/26	Ji-Seong So	Buy	Director	435	0.0006%
3/3/26	Young-Chul Yoon	Buy	Director	109	0.0002%
2/27/26	Eun-seong Hwang	Buy		4,000	0.0072%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMICOGEN, INC.	+5.38%	+5.47%	-69.71%	-86.83%	58.88M
WUXI APPTEC CO., LTD.	+1.23%	+0.35%	+51.62%	+87.98%	55.92B
ARGENX SE	+2.43%	+8.56%	+65.26%	+70.47%	56.67B
BIONTECH SE	+0.25%	+0.55%	-19.67%	-15.22%	23.28B
INSMED INCORPORATED	+0.72%	-0.05%	+3.84%	+409.54%	23.28B
WUXI BIOLOGICS (CAYMAN) INC.	-0.36%	+5.73%	+30.99%	-3.58%	20.54B
GENMAB A/S	-0.74%	+1.20%	+25.89%	-29.79%	17.78B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.44%	+5.67%	+32.54%	+544.11%	15.9B
PHARMAESSENTIA CORPORATION	-2.54%	-8.73%	+164.11%	+289.45%	14.64B
EXELIXIS, INC.	+1.22%	-0.05%	+22.58%	+182.63%	13.99B
Average	+0.61%	+1.68%	+30.75%	+144.88%	24.21B
Weighted average by Cap.	+0.68%	+3.18%	+43.57%	+136.03%

	2024	2025
Net sales	174B 118M 103M 96.15M 88.43M 166M 11.4B 169M 1.15B 448M 5.56B 442M 432M 19.28B	41.98B 28.46M 25.03M 23.25M 21.38M 40.1M 2.76B 40.82M 278M 108M 1.34B 107M 105M 4.66B
Net income	-52.79B -35.79M -31.47M -29.24M -26.89M -50.43M -3.47B -51.33M -350M -136M -1.69B -134M -131M -5.86B	-29.96B -20.31M -17.86M -16.59M -15.26M -28.62M -1.97B -29.13M -198M -77.39M -959M -76.24M -74.59M -3.33B
Net Debt	112B 75.59M 66.48M 61.76M 56.8M 107M 7.32B 108M 739M 288M 3.57B 284M 278M 12.39B	86.91B 58.91M 51.81M 48.13M 44.27M 83.02M 5.71B 84.51M 576M 225M 2.78B 221M 216M 9.65B